Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study

Clinical Snapshot

Key Findings

• P Value: p<0.0001 for AUC comparison

• Effect Size: AUC difference of 0.07 favouring [18F]MK6240 (0.93 vs 0.86)

• Primary Outcome: Discriminative accuracy for Alzheimer's disease-related cognitive impairment

• Nnt Or Sensitivity: Sensitivity: [18F]MK6240 identified 23 additional MTL-positive cases per 100 cognitively unimpaired Aβ-positive individuals

• Confidence Interval: [18F]MK6240: 95% CI 0.89-0.95; [18F]flortaucipir: 95% CI 0.75-0.91

Clinical Application

Currently limited by [18F]MK6240's investigational status, though [18F]flortaucipir is clinically available. Requires specialised PET facilities and expertise Relevant for Australian memory clinics and research centres. TGA approval would be required for [18F]MK6240 clinical use. May inform PBS listing considerations for tau PET tracers in dementia assessment Patients across the cognitive spectrum being evaluated for Alzheimer's disease, particularly those requiring tau PET for diagnostic clarification or clinical trial screening

Abstract

BACKGROUND: Tau PET imaging has emerged as a critical biomarker for Alzheimer's disease, informing diagnosis, staging, and therapeutic selection. We investigated whether PET tracer selection alters tau detection. METHODS: We conducted a prospective, multicentre, non-randomised, within-participant comparison of [18F]flortaucipir (Tauvid), currently used in clinical settings in the USA and Europe, and [18F]MK6240, an investigational tau PET tracer. Participants were recruited from eight north American sites and underwent tau PET, amyloid-β (Aβ) PET, and detailed cognitive assessments. Tau PET with both agents was acquired within a 45-day window. Coprimary outcomes were the discriminative accuracy for Alzheimer's disease-related cognitive impairment and the frequency of tau positivity in early medial temporal lobe (MTL) and late neocortical regions. The study is registered with ClinicalTrials.gov, NCT05361382. FINDINGS: Between March 2, 2022, and Aug 27, 2025, 775 individuals were enrolled, with 682 completing all procedures (373 [55%] female, 309 [45%] male; 38 [6%] aged 19-27 years, 214 [31%] aged 50-65 years, and 430 [63%] aged 65-89 years). 32 (5%) participants identified as Hispanic or Latino. 637 (93%) identified as White, 24 (4%) as Black or African American, 16 (2%) as Asian, and five (1%) as other. In addition, 49 (7%) individuals were identified as being from a rural area. [18F]MK6240 showed greater accuracy than [18F]flortaucipir in distinguishing Alzheimer's disease from non-Alzheimer's disease impairment (area under the curve 0·93, 95% CI 0·89-0·95 vs 0·86, 0·75-0·91; p<0·0001). Among the older adults, tau positivity status was concordant in 560 (87%) for MTL and 603 (94%) for neocortical regions. In cognitively unimpaired participants, [18F]MK6240 identified twice as many MTL-positive cases as [18F]flortaucipir (n=54 [15%] vs n=23 [6%]). Prevalence ratio in Aβ-positive was 2·43 (95% CI 1·50-3·94; p=0·0003), identifying 23 additional cases per 100. Among discordant cases, 75 (89%) were [18F]MK6240-positive only and had higher Aβ burden (p<0·0001), APOEε4 frequency (p<0·0001), and cognitive impairment (p=0·0043) than those negative on both tracers. Neocortical tau positivity was more frequent with [18F]MK6240 than with [18F]flortaucipir in cognitively impaired individuals (80 [28%] vs 46 [16%]). Prevalence ratio in Aβ-positive was 1·74 (95% CI 1·32-2·29; p<0·0001), identifying 15 additional mild cognitive impairment and 21 dementia cases per 100. INTERPRETATION: Tau PET tracer selection influences the frequency of detection of tau pathology across the ageing and Alzheimer's disease spectrum. Compared with [18F]flortaucipir, [18F]MK6240 identified more individuals with tau pathology in cognitively unimpaired and cognitively impaired individuals, with direct implications for patient stratification in clinical trials and more precise guidance for therapeutic decision-making. FUNDING: National Institute on Aging.

References

1. 1.Povala, G., Bellaver, B., Lussier, F. Z., Amaral, L., Bauer-Negrini, G., Ferreira, P. C. L., Rocha, A., Ruppert, E., Medeiros, M. S., Tissot, C., Jagust, W. J., Masdeu, J. C., Fortea, J., Tudorascu, D. L., Soleimani-Meigooni, D. N., Lowe, V., Oh, H., Pascual, B., Gordon, B. A., Rosa-Neto, P., Baker, S., & Pascoal, T. A. (2026). Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study. *Lancet*, Article 10.1016/S0140-6736(26)00417-4. https://doi.org/10.1016/S0140-6736(26)00417-4